HomeCompareTRUMY vs JNJ

TRUMY vs JNJ: Dividend Comparison 2026

TRUMY yields 1.39% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRUMY wins by $551.0K in total portfolio value
10 years
TRUMY
TRUMY
● Live price
1.39%
Share price
$13.70
Annual div
$0.19
5Y div CAGR
75.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$581.3K
Annual income
$384,516.52
Full TRUMY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — TRUMY vs JNJ

📍 TRUMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRUMYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRUMY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRUMY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRUMY
Annual income on $10K today (after 15% tax)
$117.88/yr
After 10yr DRIP, annual income (after tax)
$326,839.04/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, TRUMY beats the other by $322,853.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRUMY + JNJ for your $10,000?

TRUMY: 50%JNJ: 50%
100% JNJ50/50100% TRUMY
Portfolio after 10yr
$305.8K
Annual income
$194,602.96/yr
Blended yield
63.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

TRUMY
No analyst data
Altman Z
4.2
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRUMY buys
0
JNJ buys
0
No recent congressional trades found for TRUMY or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRUMYJNJ
Forward yield1.39%2.13%
Annual dividend / share$0.19$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR75.5%28%
Portfolio after 10y$581.3K$30.3K
Annual income after 10y$384,516.52$4,689.40
Total dividends collected$542.2K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TRUMY vs JNJ ($10,000, DRIP)

YearTRUMY PortfolioTRUMY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,943$243.39$10,592$272.30+$351.00TRUMY
2$12,146$436.87$11,289$357.73+$857.00TRUMY
3$13,792$795.32$12,123$472.89+$1.7KTRUMY
4$16,238$1,481.20$13,141$629.86+$3.1KTRUMY
5$20,236$2,860.42$14,408$846.81+$5.8KTRUMY
6$27,499$5,846.46$16,021$1,151.60+$11.5KTRUMY
7$42,455$13,031.07$18,122$1,588.22+$24.3KTRUMY
8$78,424$32,998.00$20,930$2,228.20+$57.5KTRUMY
9$183,893$99,978.77$24,792$3,191.91+$159.1KTRUMY
10$581,282$384,516.52$30,274$4,689.40+$551.0KTRUMY

TRUMY vs JNJ: Complete Analysis 2026

TRUMYStock

Terumo Corporation engages in the manufacture and sale of medical products and equipment worldwide. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.

Full TRUMY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this TRUMY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRUMY vs SCHDTRUMY vs JEPITRUMY vs OTRUMY vs KOTRUMY vs MAINTRUMY vs ABBVTRUMY vs MRKTRUMY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.